Lennox-Gastaut Syndrome

Cannabis-derived epilepsy drug on the horizonA pharmaceutical formulation of purified cannabidiol, a cannabinoid without euphoric side effects, is expected to launch in the second half of this year.
Antiepileptic drug can now be used in pediatric patientsFDA has expanded the indication for topiramate (Qudexy XR, Upsher-Smith Laboratories) extended-release capsules within the pediatric population.
FDA approves Banzel to treat seizures associated with LGS in pediatric patientsFDA has approved rufinamide (Banzel, Eisai) for the treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients.
FDA drug approvals-February 2015FDA actions in brief, priority review, breakthrough designations, orphan drug designations
FDA warns of serious skin reactions with clobazamFDA issued a warning to the public that clobazam (Onfi) can cause Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) at any time during treatment. These serious skin reactions are rare, but can cause permanent harm and may lead to death, according to an FDA drug safety communication.